Happy Holidays. Keep checking for new content.

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

by Jim Barney on July 2, 2017

Share

Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months.

Read the article here.

{ 0 comments… add one now }

Previous post:

Next post: